S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00109837
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), and giving the drugs in different combinations may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/05/2015
Locations: Providence Saint Joseph Medical Center - Burbank, Burbank, California +77 locations
Conditions: Leukemia
Register for Updates
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01055301
Withdrawn
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide and lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, cisplatin, doxorubicin hydrochloride, cyclophosphamide, etoposide, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2015
Locations: Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana +20 locations
Conditions: Multiple Myeloma, Plasma Cell Myeloma
Register for Updates
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
NCT00723658
Withdrawn
RATIONALE: Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. Giving combination chemotherapy together with bortezomib, thalidomide, and rituximab before an autologous peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. More chemotherapy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut +28 locations
Conditions: Lymphoma
Register for Updates
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
NCT00002849
Completed
RATIONALE: Chemotherapy plus interferon alfa may be effective for primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus interferon alfa in treating patients who have primary systemic amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Rebecca and John Moores UCSD Cancer Center, La Jolla, California +39 locations
Conditions: Multiple Myeloma
Register for Updates
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
NCT00555906
Completed
This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® \[bortezomib\] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2015
Locations: Northwestern Medical Faculty Foundation, Chicago, Illinois +18 locations
Conditions: Multiple Myeloma
Register for Updates
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
NCT02353468
Terminated
This phase II trial studies how well giving bortezomib, lenalidomide, and dexamethasone together works in treating patients with multiple myeloma undergoing stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the gr... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
02/23/2015
Locations: University of Colorado, Aurora, Colorado
Conditions: Refractory Plasma Cell Myeloma
Register for Updates
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT02353572
Terminated
This phase I/II trial studies the safety and best dose of melphalan and bortezomib when given prior to an autologous stem cell transplant and to see how well they work in treating patients with multiple myeloma. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may help melphalan work better by making cancer cells more sensitive to th... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/23/2015
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Register for Updates
Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
NCT01581151
Unknown
This study seeks to compare dexamethasone implant with rescue intravitreal ranibizumab to monthly intravitreal ranibizumab for the treatment of macular edema secondary to branch or central retinal vein occlusion. This is based on the null hypothesis that dexamethasone implant with rescue ranibizumab has inferior best corrected visual acuity at six months compared to monthly ranibizumab alone.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/19/2015
Locations: Wills Eye Retina Service, Philadelphia, Pennsylvania
Conditions: Retinal Vein Occlusion
Register for Updates
Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder
NCT00815204
Completed
Approximately, post-traumatic stress disorder (PTSD) occurs in 8% of the adult population over time. Exposure to traumatic events increases the risk of poor physical health and often leads to disability. The biology of PTSD is continually being explored in order to help find better treatments for this debilitating disorder. In our study, we propose to further our understanding of PTSD. Prior research has found that patients with PTSD have changes in the stress hormone pathway. In this pathway, t... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/02/2015
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Posttraumatic Stress Disorder
Register for Updates
The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade
NCT02005575
Unknown
The proposed study is a randomized, double-blinded, non-placebo-controlled evaluation of the effect of the addition of dexamethasone to intraoperative intercostal nerve block bupivicaine solutions on the duration of pain relief and post operative pulmonary function.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/02/2015
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Post Minimally Invasive Thorascopic Surgical Pain
Register for Updates
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
NCT01537861
Terminated
Based on the pre-clinical data the investigators hypothesize that G-CSF treatment in patients with multiple myeloma will generate a 'hostile' bone marrow microenvironment for myeloma cells, depriving them of key support signals and rendering them more sensitive to chemotherapy. The investigators therefore propose to do an initial pilot study 1) to explore the safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with bortezomib-, carfilzom... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2015
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Multiple Myeloma
Register for Updates
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
NCT00060684
Completed
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2015
Locations: Arizona Clinical Research Center, Tucson, Arizona +3 locations
Conditions: Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
Register for Updates